Ryan Allway March 1st, 2023 News, Top News Toronto, ON – TheNewswire – March 1, 2023 – Hill Street Beverage Company Inc. (TSXV:HILL) (OTC:HSEEF) (“Hill Street” or the “Company”), a progressive bioscience implementation company that utilizes new technologies to provide innovative cannabis solutions and non-alcoholic beverage products globally, is pleased to announce the... Read more
Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement
November 7, 2022
Skye will continue to pursue Canadian Securities Exchange listing following closing of transaction targeting glaucoma VANCOUVER, BC, November 7, 2022– Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (CSE: EMH; OTCQB: EMHTF) and Skye Bioscience, Inc. (“Skye”) (OTCQB: SKYE) announced today that they intend to close the previously announced Plan... Read more
Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date
September 1, 2022
Ryan Allway September 1st, 2022 News, Top News San Diego, California, Sept. 01, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announces that it has filed its definitive proxy statement related to... Read more
Ryan Allway June 30th, 2022 News, Top News Lead drug candidate has shown superior and longer-lasting lowering of intraocular pressure, a risk factor associated with glaucoma, in preclinical studies San Diego, California–(Newsfile Corp. – June 30, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical... Read more
Ryan Allway June 27th, 2022 News, Top News Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for... Read more
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer
March 28, 2022
Ryan Allway March 28th, 2022 News, Top News VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive... Read more
Ryan Allway March 30th, 2020 Uncategorized The COVID-19 outbreak has become a major source of stress over the past several weeks. In addition to the fear and anxiety of disease, quarantines and “stay at home” orders have contributed to stress levels, leading to poor sleep, unhealthy eating, and other... Read more
Israel Begins Cannabis Exports to Meet Unmet Medical Needs
March 25, 2020
Ryan Allway March 25th, 2020 App, Exclusive, News, Top Story Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research... Read more
Canadian Cannabis Success Being Replayed in Israel Right Now, Featuring an Exclusive Isracann Biosciences CEO Video Interview Part #1
December 18, 2019
Ryan Allway December 18th, 2019 App, Exclusive, News, Top News After experiencing success with the legalization of cannabis in Canada, Darryl Jones was looking for the next big cannabis opportunity. As it happens, that opportunity was 11,000 miles away from Vancouver in Israel. Fast forward and Jones is now... Read more
What if Employers had a Convenient Way to Test for Cannabis Use?
October 11, 2019
Robin Lefferts October 11th, 2019 App, Exclusive, News, Top Story With cannabis legalization sweeping across North America after decades of prohibition, there are some natural concerns surrounding the introduction of the drug to the legal marketplace. In the area of safety, most of the questions have surrounded the issue... Read more
